
Zydus Lifesciences Gains USFDA Nod for Celecoxib
Zydus Lifesciences saw a slight increase in its share price after receiving USFDA approval for its Celecoxib Capsules, a nonsteroidal anti-inflammatory drug. Trading at Rs 973.55, the approval covers multiple strengths of the medication, which is designed to alleviate pain and inflammation from conditions like arthritis and menstrual pain. The capsules will be manufactured at Zydus's facility in Ahmedabad. With this approval, Zydus continues to expand its portfolio, now holding 428 approvals since 2003.